杭齒前進(601177.SH):相關項目當前尚無相關產品,未形成銷售收入
格隆匯3月7日丨杭齒前進(601177.SH)公佈,根據浙江省科學技術廳《關於下達2025年度“尖兵領雁+X”科技計劃第一批項目的通知》及立項清單,公司所承擔的項目,研發週期預計爲2年。目前,上述項目尚處於研究起步階段,項目研究成果尚存在不確定性,當前尚無相關產品,未形成銷售收入,且根據項目計劃,預計2025年不形成銷售收入。敬請廣大投資者注意二級市場交易風險,理性決策,審慎投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.